logo

For the Inventor, By the Inventor

Corvallis, OR, United States of America

Avi Biopharma, Inc.


USPTO Granted Patents = 50

% Expired Patents = 30.0



Trademarks = 2

Forward Citations = 2,023

Loading Chart...
Loading Chart...

40 inventors (with patents filed for the assignee):

goldMedal Patrick L Iversen (43 out of 95 patents)

silverMedal Dwight D Weller (22 out of 61 patents)

bronzeMedal David A Stein (14 out of 24 patents)

4.  Sina Bavari (5 out of 28 patents)

5.  Bruce L Geller (4 out of 16 patents)

6.  Hong M Moulton (4 out of 9 patents)

7.  Robert Hudziak (3 out of 6 patents)

8.  Jed N Hassinger (3 out of 8 patents)

9.  Dan V Mourich (3 out of 11 patents)

10.  James E Summerton (3 out of 22 patents)

11.  Michelle H Nelson (2 out of 4 patents)

12.  Andrew D Kroeker (2 out of 4 patents)

13.  Lucas D Tilley (2 out of 6 patents)

14.  Jesse D Deere (2 out of 3 patents)

15.  Stephen H Bartelmez (2 out of 3 patents)


Core Competencies:
Antisense Oligonucleotides
Antiviral Compounds
Oligonucleotide Delivery
Filovirus Treatment
Cancer Treatment
Immunomodulatory Agents
Morpholino Oligomers
Bacterial Infections
Muscle Atrophy
RNA Detection
Peptide Conjugates
Microbubble Compositions

50 patents:

1. 9572899 - Compositions for enhancing transport of molecules into cells (2017-02-21),
2. 8524684 - Antisense antiviral compounds and methods for treating a filovirus infection (2013-09-03),
3. 8436163 - Splice-region antisense composition and method (2013-05-07),
4. 8415313 - Antisense oligomers and methods for inducing immune tolerance and immunosuppression (2013-04-09),
5. 8357664 - Antisense antiviral compound and method for treating influenza viral infection (2013-01-22),
6. 8329668 - Antisense antiviral compound and method for treating picornavirus infection (2012-12-11),
7. 8314072 - Antisense antibacterial method and compound (2012-11-20),
8. 8299206 - Method of synthesis of morpholino oligomers (2012-10-30),
9. 8198429 - Antisense antiviral compounds and methods for treating a filovirus infection (2012-06-12),
10. 8168604 - Antisense antiviral compounds and methods for treating a filovirus infection (2012-05-01),
11. 8129352 - Antisense antiviral compound and method for treating ssRNA viral infection (2012-03-06),
12. 8084433 - Antisense antiviral compound and method for treating ssRNA viral infection (2011-12-27),
13. 8076476 - Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits (2011-12-13),
14. 8067571 - Antibacterial antisense oligonucleotide and method (2011-11-29),
15. 8067569 - Splice-region antisense composition and method (2011-11-29),
Avi Biopharma, Inc., based in Corvallis, Oregon, specializes in the development of innovative therapeutics utilizing antisense oligonucleotide technology. The company focuses on creating antiviral compounds and advanced oligonucleotide delivery systems aimed at treating various diseases, including filovirus infections and cancer. Additionally, Avi Biopharma is engaged in research on immunomodulatory agents and morpholino oligomers, contributing to the fight against bacterial infections and enhancing therapeutic efficacy in diverse medical applications.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

50 Patents

#6 in Corvallis, OR

#78 in Oregon

#6,999 in US

#13,996 in the World

Corvallis, OR (US)
Corvallis, OR, United States of America

Avi Biopharma, Inc.

Forward Citations = 2,023

40 inventors:

goldMedal Patrick L Iversen (43 out of 95 patents)

silverMedal Dwight D Weller (22 out of 61 patents)

bronzeMedal David A Stein (14 out of 24 patents)

4.  Sina Bavari (5 out of 28 patents)

5.  Bruce L Geller (4 out of 16 patents)

Please report any incorrect information to [email protected]
Loading…